UNSPSC 51433603: Pempidine

This classification denotes a nicotinic antagonist and antihypertensive agent with the molecular formula C10H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N5I18JI9D6, chemically known as 1,2,2,6,6-pentamethylpiperidine but generally known as pempidine, which bears US NIH Compound Identifier 6603. European Medicines Agency schedules Pempidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09658MIG.

UNSPSC 51433603 Pempidine is a Commodity code that covers individual pharmaceutical products for emergency medical and institutional health care use. State and local governments procure these medications through both direct municipal purchasing and statewide cooperative agreements, typically bundled with other emergency life-support drugs or integrated into broader pharmacy benefit programs. The City of Tampa Fire Rescue and state health agencies represent the primary demand drivers, with acquisitions driven by operational needs in emergency response and managed care settings rather than routine pharmacy retail. Issuing bodies span municipal fire and rescue departments, state health and human services commissions, and cooperative purchasing alliances that serve multi-jurisdictional government agencies and institutional health care systems.

Recent activity clusters in Florida and Minnesota, with emerging procurement in Texas. The City of Tampa Purchasing Department issued IFB 26P00188 on April 24, 2026, seeking Advanced Life Support Medications for Tampa Fire Rescue with a due date of April 8, 2026 and an estimated contract value of $40,000.00, requiring delivery within ten calendar days and nine-month minimum shelf life. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, exploring direct-to-manufacturer pharmacy benefit capabilities for self-insured state and local employee health plans, signaling early-stage procurement strategy development in that state.